Abstract
Tumor necrosis factor-alpha (TNF-α) plays a central role in immune response regulation. Due to the correlation between elevated TNF-α production and a range of diseases, inhibiting the interaction of this protein with its native receptors as a therapeutic avenue has been thoroughly explored. Despite advancements in the development of lead TNF-α inhibitors, concerns remain regarding immunogenicity and loss of activity in vivo. To facilitate the discovery of stable and less immunogenic therapeutic modalities, we describe a rapid synthesis protocol that capitalizes on the synergy between automated fast-flow peptide synthesis (AFPS) technology, native chemical ligation (NCL), and high-throughput screening of folding conditions to arrive at functional synthetic proteins, native and mirror-image TNF-α. Specifically, an NCL reaction using only two fragments that were readily produced by AFPS afforded synthetic L- and D-TNF-α in milligram quantities (up to 5.5 mg, ~28% yield). Subsequent oxidation and dialysis led to folded TNF-α homotrimers, exhibiting analogous characteristics to the recombinant TNF-α. Overall, this innovative approach can serve as a general protocol for accessing proteins that are intractable by modern protein synthesis methods, therefore enabling the development of novel and stable therapeutics.
Supplementary materials
Title
Supporting Information
Description
Materials, methods, and analytical characterization.
Actions